Evidence map›Paper›PMID 35718416›Full record

ReviewHeart failure clinics2022

Understanding Myocardial Metabolism in the Context of Cardio-Oncology.

Jing Liu, Zsu-Zsu Chen, Jagvi Patel, Aarti Asnani

Abstract readReview
In one paragraph

Review in Heart failure clinics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jing LiuDivision of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA.
Zsu-Zsu ChenDivision of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA.
Jagvi PatelDivision of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA.
Aarti AsnaniDivision of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215, USA. Electronic address: aasnani@bidmc.harvard.edu.
Harvard University · USBeth Israel Deaconess Medical Center · US

Funding

CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin CardiomyopathyK08HL145019 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI ASNANI, AARTI · 2019 to 2023
$837k
Phosphatidylcholine and cholesterol ester biomarkers of type 2 diabetes and preventive treatment effectsK23DK127073 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHEN, ZSU-ZSU · 2021 to 2025
$824k
NHLBI NIH HHS K08 HL145019NIDDK NIH HHS K23 DK127073
6 · The paper itself

Abstract

Cardiovascular events, ranging from arrhythmias to decompensated heart failure, are common during and after cancer therapy. Cardiovascular complications can be life-threatening, and from the oncologist's perspective, could limit the use of first-line cancer therapeutics. Moreover, an aging population increases the risk for comorbidities and medical complexity among patients who undergo cancer therapy. Many have established cardiovascular diagnoses or risk factors before starting these therapies. Therefore, it is essential to understand the molecular mechanisms that drive cardiovascular events in patients with cancer and to identify new therapeutic targets that may prevent and treat these 2 diseases. This review will discuss the metabolic interaction between cancer and the heart and will highlight current strategies of targeting metabolic pathways for cancer treatment. Finally, this review highlights opportunities and challenges in advancing our understanding of myocardial metabolism in the context of cancer and cancer treatment.

Indexed as

Antineoplastic AgentsCardiovascular DiseasesHeart DiseasesNeoplasmsAgedCardiotoxicityHeartHumansMedical OncologyAntineoplastic AgentsCardio-oncologyChemotherapyHeart failureMetabolic disordersMyocardial metabolism

Identifiers

PMID35718416
PMCPMC11997845
OpenAlexW4283012399

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.